In its second pharma deal, Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform. Read More
Merck, Dewpoint unite to find HIV cure in deal worth up to $305M
Reading Time: < 1 minute